ArticleBMC gastroenterology2025
Prevalence, demographic characteristics and clinical profile of metabolic dysfunction-associated fatty liver disease among adult patients attending tertiary hospitals in Dodoma, Tanzania. a cross-sectional study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlobally, metabolic dysfunction-associated fatty liver disease (MAFLD) has become one of the leading causes of liver disease, attributed to the rapid increase in obesity. There is paucity of data on the burden of MAFLD in Tanzania. The study assessed MAFLD prevalence and associated factors among adult patients in Dodoma,
methodsFrom November 2023 to March 2024 adult patients was recruited at tertiary hospitals. MAFLD was diagnosed based on evidence of steatosis on imaging plus any one of five cardio metabolic risk factors, such as overweight or obesity (BMI ≥ 25 kg/m2), diabetes mellitus type 2, hypertension, dyslipidemia, and metabolic dysregulation. Demographic and clinical characteristics were collected and analyzed to identify risk factors of MAFLD. The chi-squared test was used to determine if there is a proportional between categorical data. Logistic regression analysis was used to check for associated factors; significance was defined as a p-value < 0.05. The Institutional Research Ethics Committee (IRREC) of University of Dodoma (UDOM) approved the study, and informed consent was obtained.
resultsA total of 351 patients were recruited, of whom 186(53%) were females, and the median age was 62 (IQR 52–70) years. The prevalence of MAFLD was 21.9%. Among patients with MAFLD 12(15.6%) were found to have advanced fibrosis. Compared to non MAFLD subjects, MAFLD patients had elevated liver enzymes with a P value (< 0.001),T2DM (OR: 3.9; 95% CI (2.1–7.2, p < 0.001), dyslipidemia (OR: 2.3; 95% CI 1.2–4.7, p = 0.013), obesity (OR: 2.0; 95% CI (1.1–3.7, p = 0.016),alcohol consumption(OR:2.2;95% CI(1.2–4.1, P = 0.007),smoking( OR 2.6 ;95% CI (1.4–4.8, p < 0.001), and sedentary lifestyle (OR: 2.3; 95% CI (1.2–4.2, p = 0.005) were associated with MAFLD.
conclusionThe high prevalence of MAFLD indicates its emergence as a significant health concern in daily clinical practice in our setting, potentially leading to increase morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.